{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:45:17Z","timestamp":1790437517189,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.diagmicrobio.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T15:00:49Z","timestamp":1535641249000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["What's new in the treatment of multidrug-resistant gram-negative infections?"],"prefix":"10.1016","volume":"93","author":[{"given":"Yoonsun","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Farghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth T.","family":"Housman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0005","author":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) \u00b1 Metronidazole (MTZ) Versus Meropenem (MER) \u00b1 Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. - Full Text View - ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0010","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0015","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/cid\/ciw398","article-title":"High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-\u03b2-lactamase production in enterobacteriaceae bloodstream infections at a major cancer center","volume":"63","author":"Aitken","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0020","author":"Allergan plc"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0030","series-title":"Avycaz\u00ae [prescribing information]","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0040","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0045","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0050","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0055","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/AAC.01720-16","article-title":"Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0060","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0065","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0070","series-title":"Twentieth Informational Supplement M100\u2013S20","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0080","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0085","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0090","series-title":"Presented at: ECCMID 2017, Vienna, Austria. Presentation","article-title":"Plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results of the EPIC Study","author":"Cloutier","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0100","first-page":"147","article-title":"New Delhi metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised","volume":"58","author":"Deshpande","year":"2010","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0105","author":"Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE) - Full Text View - ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dkp029","article-title":"Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK","volume":"63","author":"Doumith","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0120","author":"Efficacy and Safety of Imipenem+Cilastatin\/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) - Full Text View - ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0125","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0135","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","author":"Fraile-Ribot","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-17","article-title":"In Vivo Emergence of Resistance to Novel Cephalosporin-\u03b2-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 \u03b2-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0145","series-title":"Poster Presented at: ECCMID 2018, Madrid, Spain. Poster","article-title":"Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Clinical Isolates","author":"Hackel","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0150","series-title":"Poster Presented at ECCMID 2018, Madrid, Spain. Poster","article-title":"In Vitro Activity of Cefepime in Combination with VNRX-5133 Against Meropenem and\/or Cefepime Resistant Clinical Isolates of Pseudomonas aeruginosa","author":"Hackel","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum \u03b2-Lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0165","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0175","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0180","author":"Imipenem\/Relebactam\/Cilastatin Versus Piperacillin\/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) - Full Text View - ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0185","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0190","series-title":"Poster presented at: IDWeek 2017, San Diego, CA. Poster","article-title":"Meropenem-Vaborbactam (VABOMERE) vs. Best Available Therapy for CRE Infections: TANGO II Randomized, Controlled Phase 3 Study Results","author":"Kaye","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0075","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0195","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0200","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M112.348540","article-title":"Exploring the role of a conserved class A residue in the \u03a9-Loop of KPC-2 \u03b2-lactamase: a mechanism for ceftazidime hydrolysis","volume":"287","author":"Levitt","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0205","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0210","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0215","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","article-title":"Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates","volume":"34","author":"Livermore","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0220","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1574-6968.2008.01126.x","article-title":"Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli","volume":"282","author":"Mammeri","year":"2008","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can Ceftazidime-Avibactam and Aztreonam Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0240","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2015.10.008","article-title":"Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"85","author":"Martirosov","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0245","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/AAC.44.12.3322-3327.2000","article-title":"Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa","volume":"44","author":"Masuda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0250","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0255","series-title":"Poster presented at: IDWeek 2017, San Diego, CA. Poster","article-title":"Improved Outcomes With Plazomicin Compared With Colistin in Patients With Bloodstream Infections Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results From the CARE Study","author":"McKinnell","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0260","first-page":"303","article-title":"Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa","volume":"16","author":"Meletis","year":"2012","journal-title":"Hippokratia"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/dkn434","article-title":"Emergence and widespread dissemination of OXA-23, -24\/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY surveillance program","volume":"63","author":"Mendes","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0270","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01737-16","article-title":"The Acinetobacter Outer Membrane Contains Multiple Specific Channels for Carbapenem \u03b2-Lactams as Revealed by Kinetic Characterization Analyses of Imipenem Permeation into Acinetobacter baylyi Cells","volume":"61","author":"Mor\u00e1n-Barrio","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0275","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.bmc.2007.11.074","article-title":"Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure","volume":"16","author":"Murano","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0280","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1128\/AAC.49.4.1432-1440.2005","article-title":"Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins","volume":"49","author":"Mussi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0285","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0290","series-title":"Principles and Practice of Infectious Diseases","first-page":"235","article-title":"Molecular Mechanisms of Antibiotic Resistance in Bacteria","author":"Opal","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0295","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"Role of the Outer Membrane and Porins in Susceptibility of \u03b2-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam","volume":"60","author":"Pag\u00e8s","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0300","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a Successful Pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0305","author":"Pipeline"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0310","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/AAC.05136-14","article-title":"Evaluation of the activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"59","author":"Pitart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0315","author":"Plazomicin sulfate Injection Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC)"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0320","author":"Plazomicin: the first clinical candidate from our gram-negative antibiotic discovery engine"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0325","author":"Plazomicin: the first clinical candidate from our gram-negative antibiotic discovery engine"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0330","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","article-title":"Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology","volume":"12","author":"Poirel","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0335","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/ofid\/ofx163.1399","volume":"4","author":"Portsmouth","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0340","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.50.5.1633-1641.2006","article-title":"Interplay of Efflux System, ampC, and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical Isolates","volume":"50","author":"Quale","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0345","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0350","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nmni.2015.06.002","article-title":"High prevalence of blaoxa-23 in Acinetobacter spp. and detection of blandm-1 in A. soli in Cuba: report from National Surveillance Program (2010-2012)","volume":"7","author":"Quinones","year":"2015","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0360","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centers (2015-17)","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0365","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ja.2006.31","article-title":"Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem","volume":"59","author":"Sakyo","year":"2006","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0370","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0375","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.08.007_bb0380","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0385","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-17","article-title":"In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0390","author":"Shionogi"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0395","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0400","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0405","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/JB.00590-16","article-title":"Klebsiella pneumoniae Major Porins OmpK35 and OmpK36 Allow More Efficient Diffusion of \u03b2-Lactams than Their Escherichia coli Homologs OmpF and OmpC","volume":"198","author":"Sugawara","year":"2016","journal-title":"J Bacteriol"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0410","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1093\/jac\/dkw082","article-title":"In vitro pharmacokinetics\/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms","volume":"71","author":"Sy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0415","series-title":"Tetraphase Pharmaceuticals","author":"Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0420","unstructured":"Tetraphase\u2019s eravacycline misses endpoints in phase 3 flop | FierceBiotech. Available at: \/biotech\/tetraphase-s-eravacycline-misses-endpoints-phase-3-flop; accessed on February 2018."},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0425","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","volume":"50","author":"The 10 \u00d7 \u201920 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0430","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0435","author":"Tracking Carbapenem-resistant Enterobacteriaceae"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0440","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0445","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0450","series-title":"Vabomere\u00ae [prescribing information]","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0455","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0460","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0465","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0470","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0475","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1099\/jmm.0.008094-0","article-title":"Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency","volume":"58","author":"Wang","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0480","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0485","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0490","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0495","series-title":"Poster presented at: IDWeek 2017, San Diego, CA. Poster","article-title":"Meropenem-Vaborbactam (VABOMERE) vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Primary Outcomes by Site of Infection","author":"Wunderink","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0500","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3892\/mmr.2016.5538","article-title":"Resistant mechanisms and molecular epidemiology of imipenem-resistant Acinetobacter baumannii","volume":"14","author":"Xiao","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0505","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-Lactams Strike Back: Ceftazidime-Avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0510","series-title":"Zerbaxa\u00ae [prescribing information]","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0515","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-Avibactam: a Novel Cephalosporin\/\u03b2-lactamase Inhibitor Combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2018.08.007_bb0520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318303018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318303018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:26Z","timestamp":1760003546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318303018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0732889318303018"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.08.007","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What's new in the treatment of multidrug-resistant gram-negative infections?","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}